Target Price | $95.37 |
Price | $97.34 |
Deviation | 2.02% |
Number of Estimates | 30 |
30 Analysts have issued a price target Lam Research 2026 . The average Lam Research target price is $95.37. This is 2.02% lower than the current stock price. The highest price target is $131.25 34.84% , the lowest is $70.70 27.37% . | |
A rating was issued by 37 analysts: 29 Analysts recommend Lam Research to buy, 8 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Lam Research stock has an average upside potential 2026 of 2.02% . Most analysts recommend the Lam Research stock at Purchase. |
33 Analysts have issued a sales forecast Lam Research 2025 . The average Lam Research sales estimate is $18.6b . This is 8.64% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $19.2b 12.29% , the lowest is $17.7b 3.28% .
This results in the following potential growth metrics:
2024 | $14.9b | 14.48% |
---|---|---|
2025 | $18.6b | 24.90% |
2026 | $19.1b | 2.41% |
2027 | $21.2b | 11.27% |
2028 | $22.6b | 6.53% |
2029 | $24.8b | 9.93% |
21 Analysts have issued an Lam Research EBITDA forecast 2025. The average Lam Research EBITDA estimate is $6.3b . This is 11.34% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.6b 16.67% , the lowest is $5.7b 1.06% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.7b | 16.89% |
---|---|---|
2025 | $6.3b | 34.68% |
2026 | $6.3b | 0.87% |
2027 | $7.2b | 15.62% |
2028 | $7.9b | 9.17% |
2029 | $8.7b | 10.72% |
2024 | 31.43% | 2.83% |
---|---|---|
2025 | 33.89% | 7.82% |
2026 | 32.81% | 3.19% |
2027 | 34.09% | 3.90% |
2028 | 34.93% | 2.46% |
2029 | 35.18% | 0.72% |
33 Lam Research Analysts have issued a net profit forecast 2025. The average Lam Research net profit estimate is $5.2b . This is 12.68% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $5.5b 17.41% , the lowest is $4.9b 6.04% .
This results in the following potential growth metrics and future Net Margins:
2024 | $3.8b | 15.14% |
---|---|---|
2025 | $5.2b | 37.13% |
2026 | $5.3b | 0.14% |
2027 | $6.1b | 16.91% |
2028 | $6.9b | 11.79% |
2029 | $7.8b | 14.10% |
2024 | 25.68% | 0.78% |
---|---|---|
2025 | 28.20% | 9.81% |
2026 | 27.57% | 2.23% |
2027 | 28.97% | 5.08% |
2028 | 30.40% | 4.94% |
2029 | 31.55% | 3.78% |
33 Analysts have issued a Lam Research forecast for earnings per share. The average Lam Research EPS is $4.09 . This is 13.30% higher than earnings per share in the financial year 2024. The highest EPS forecast is $4.26 18.01% , the lowest is $3.85 6.65% .
This results in the following potential growth metrics and future valuations:
2024 | $2.90 | 12.65% |
---|---|---|
2025 | $4.09 | 41.03% |
2026 | $4.10 | 0.24% |
2027 | $4.79 | 16.83% |
2028 | $5.36 | 11.90% |
2029 | $6.11 | 13.99% |
Current | 26.96 | 30.62% |
---|---|---|
2025 | 23.79 | 11.77% |
2026 | 23.76 | 0.13% |
2027 | 20.32 | 14.48% |
2028 | 18.18 | 10.53% |
2029 | 15.93 | 12.38% |
Based on analysts' sales estimates for 2025, the Lam Research stock is valued at an EV/Sales of 6.64 and an P/S ratio of 6.69 .
This results in the following potential growth metrics and future valuations:
Current | 7.21 | 25.90% |
---|---|---|
2025 | 6.64 | 7.96% |
2026 | 6.48 | 2.35% |
2027 | 5.82 | 10.13% |
2028 | 5.47 | 6.13% |
2029 | 4.97 | 9.04% |
Current | 7.27 | 25.67% |
---|---|---|
2025 | 6.69 | 7.96% |
2026 | 6.53 | 2.35% |
2027 | 5.87 | 10.13% |
2028 | 5.51 | 6.13% |
2029 | 5.01 | 9.04% |
Analyst | Rating | Action | Date |
---|---|---|---|
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jul 01 2025 |
Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Jun 24 2025 |
B. Riley Securities |
Buy
➜
Buy
|
Unchanged | Jun 18 2025 |
Oppenheimer |
Outperform
➜
Outperform
|
Unchanged | Jun 17 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Apr 24 2025 |
Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Apr 24 2025 |
Evercore ISI Group |
Outperform
➜
Outperform
|
Unchanged | Apr 24 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Jul 01 2025 |
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Jun 24 2025 |
Unchanged
B. Riley Securities:
Buy
➜
Buy
|
Jun 18 2025 |
Unchanged
Oppenheimer:
Outperform
➜
Outperform
|
Jun 17 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Apr 24 2025 |
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Apr 24 2025 |
Unchanged
Evercore ISI Group:
Outperform
➜
Outperform
|
Apr 24 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.